Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays an important role in regulating glucose homeostasis. In this study, the applicability of circulating GLP-1 levels as an early indicator of metabolic syndrome (MetS) risk was examined. Women without diagnosed diseases were grouped according to their number of MetS risk factors (MetS RFs) (no RFs as Super-healthy, n = 61; one or two RFs as MetS risk carriers, n = 60; 3 ≤ RFs as MetS, n = 19). The circulating GLP-1 levels and homeostasis model assessment insulin resistance (HOMA-IR) scores were significantly higher in the MetS group than in the other two groups. The GLP-1 levels correlated positively with adiposity, HOMA-IR, blood pressure, and high sensitivity C-reactive protein (hs-CRP), but not with fasting glucose and lipid profiles, whose significances were maintained after adjustments for age, smoking and drinking habits, menopausal status, and total calorie intake. The GLP-1 levels also increased proportionally with the number of MetS RFs. In the MetS group, the GLP-1 levels were much higher in individuals with obesity (body mass index ≥ 25 kg/m2). In conclusion, the circulating GLP-1 level may be applicable as a potential early indicator of MetS risk in women without diagnosed diseases. Further study with a large population is needed to confirm the conclusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although there have been several studies with GLP-1RAs demonstrating a significant reduction in hsCRP [16, 17]”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597 · cited 8×
“Since IR will lead to a gradual progression from hyperinsulinemia to glucose intolerance and eventually, T2D [10], the early detection of MetS risks (including IR) is important for the prevention of chronic metabolic diseases [9].”
BackgroundInfluentialAbdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 8×
“Since IR will lead to a gradual progression from hyperinsulinemia to glucose intolerance and eventually, T2D [10], the early detection of MetS risks (including IR) is important for the prevention of chronic metabolic diseases [9].”
BackgroundInfluentialThe Global Epidemic of the Metabolic Syndrome
Saklayen, M. G. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0812-z · Cited by 3,990 · cited 1×
“more of any of the following risk factors (MetS RFs): Fasting blood glucose ≥ 100 mg/dL; waist circumference (WC) ≥ 85 cm (for females); systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg; TG ≥ 150 mg/dL; and HDL-C < 50 mg/dL (for females) [1,34].”
BackgroundGlobal burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319 · cited 3×
“8% by 2030 [5], the burden of metabolic abnormalities and the risks of chronic degenerative diseases such as CVD, diabetes, and cancer are likely to increase, as well.”
BackgroundInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The Emergence of the Metabolic Syndrome with Menopause
Carr, M. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030242 · Cited by 1,449 · cited 1×
“This hormone also has a direct effect on glucose uptake by the skeletal muscle and adipocytes, leading to the lowering of the blood glucose concentration [46,48].”
BackgroundKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 2×
“When food is ingested, the proglucagon molecules in specific intestinal enterocytes (named L-cells) are cleaved to form amidated peptides that are 30 amino acids in length, named GLP-1(7-36) amide (NH2), the predominant secreted form of GLP-1 which are then secreted into the circulatory system [17].”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 4×
“In addition, fasting levels of plasma GLP-1 were significantly higher in patients with T2D than people with normal glucose tolerance (NGT), but the postprandial plasma GLP-1 area under curve was significantly lower in patients with T2D than people with NGT [11,14].”
BackgroundInfluential
Cited by
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“Although there have been several studies with GLP-1RAs demonstrating a significant reduction in hsCRP [16, 17], the impact of semaglutide on hsCRP has yet to be fully elucidated.”
BackgroundGarvey, S. M., Mah, E., Blonquist, T. M., Kaden, V. N., & Spears, J. L. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2122668 · Cited by 93
“Circulating GLP-1 concentrations were directly correlated with metabolic syndrome and obesity in a study of 140 female participants.(59) However, it is the acute response and contribution of GLP-1 to insulin regulation that is traditionally studied in oral glucose and meal challenges.”
Ahmed, M., Kumari, N., Mirgani, Z., Saeed, A., Ramadan, A., Ahmed, M. H., & Almobarak, A. O. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00965-2 · Cited by 88
“found that GLP-1 plasma Levels can be a potential Indicator of MetS [47].”
BackgroundDieck, H. T., Schön, C., Wagner, T., Pankoke, H., Fluegel, M., & Speckmann, B. (2021) · Nutrients · doi:10.3390/nu14010143 · Cited by 38
“Recently, Wu et al. found out that several butyrate producers and functional potential for butyrate production were decreased both in prediabetes and in type 2 diabetes (T2D) [35], confirming earlier findings by Zhang et al. on reduced butyrate-production capacity during the progression of glucose intolerance [36].”
BackgroundInfluentialAnti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
“circulating GLP-1 levels as an indicator of metabolic syndrome showed that measurement of circulating GLP-1 could be considered as an early diagnostic marker of metabolic syndrome, especially obesity [67].”
Background
Metadata
- Authors
- Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y.
- Affiliations
- Dong-A University (KR)
- Chonnam National University (KR)
- Corresponding author
- Song, Juhyun
- Kim, Oh Yoen
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-03-06
- Volume
- 13
- Issue
- 3
- Pages
- 865
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC8001839
- OpenAlex
- W3133910378
- Cited by
- 21
- References
- 51
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 2
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2019R1F1A1054111, NRF-2016R1A2B4013627 and NRF-2019R1I1A3A01058861)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon-like peptide-1, metabolic syndrome, metabolic syndrome risk factors, insulin resistance, HOMA-IR, obesity, adiposity, C-reactive protein, blood pressure, women, incretins
- MeSH terms
- Adult, Blood Glucose, Blood Pressure, C-Reactive Protein, Fasting, Female, Homeostasis, Humans, Insulin, Insulin Resistance, Lipids, Predictive Value of Tests, Biomarkers, Risk Assessment, Metabolic Syndrome, Early Diagnosis, Adiposity, Glucagon-Like Peptide 1, Young Adult, Republic of Korea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women. https://app.cochat.ai/papers/10.3390/nu13030865
- The paper
- Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y. (2021). Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women. Nutrients. https://doi.org/10.3390/nu13030865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.